Evaluation of a Range of Dermo-cosmetic Products to Treat Skin and Nail Toxicity Linked to Bispecific Anti-GPRC5D Bispecific Antibodies in Multiple Myeloma Patients". Myeloma". Descriptive Pilot Study

Launched by NANTES UNIVERSITY HOSPITAL · May 13, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how well certain skincare and nail products can help patients with multiple myeloma (a type of blood cancer) manage skin and nail problems caused by a specific treatment they are receiving. The products being tested include a hand and feet serum, a nail strengthening solution, a dissolving oil, and gloves/slippers, all made from natural ingredients. The goal is to see if these products can prevent or reduce skin and nail issues for patients starting or currently undergoing treatment with a bispecific antibody therapy.

To be eligible for this study, participants must be adults diagnosed with multiple myeloma who are either starting or currently receiving the bispecific treatment and have some level of skin and nail toxicity. Patients will apply the skincare products at home according to a set schedule, and they will have regular check-ups to assess their skin and nail health. The study will last for up to six months, and participants will fill out surveys about their quality of life at the beginning, after one month, and at the end of the study. It's important to note that certain individuals, like those using specific dermatological treatments or with allergies to any of the products, will not be eligible to participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. MM patient.
• • 2. Patient starting anti-GPRC5D bispecific Ac therapy OR patient undergoing anti-GPRC5D bispecific Ac therapy with NCI-NCTCAE V5.0 grade ≥2 skin and nail toxicity.
• • 3. Patient with written consent.
• Exclusion Criteria:
• • 1. Patients treated or considering treatment with dermatological drugs (dermocorticoids) normally used for hand-foot syndrome OR dermo-cosmetic products (serum or reparative solutions) other than those tested.
• • 2. Patients with atomic dermatitis (eczema)
• • 3. Patients allergic to one or more components of the products tested.
• • 4. Pregnant or breast-feeding women.
• • 5. Patients who are minors or under legal protection (guardianship or safeguard of justice).
• • 6. Patient not affiliated to a social security scheme.